Johnson & Johnson is recalling 70,000 syringes preloaded with its Invega injectable anti-psychotic drug, the WSJ reports. Cracks have been found in the syringes that could theoretically lead to ...

NEW YORK (AP) - A unit of Johnson & Johnson has recalled 70,000 syringes of its antipsychotic drug Invega Sustenna after finding that some of the pre-filled syringes may have cracks which possibly ...

Johnson & Johnson recalled about 70,000 syringes of the antipsychotic drug Invega after finding cracks in the syringes, which could cause infections or reduced efficacy in users, the Wall Street ...

A U.S. appeals court has sided with Johnson & Johnson (NYSE:JNJ) in a patent dispute with Viatris (NASDAQ:VTRS) and Teva ...

Johnson & Johnson convinced a U.S. appeals court on Tuesday to reject a bid from generic drugmakers Teva and Viatris to ...

Janssen filed patent infringement suits in New Jersey and Delaware over proposed copy of blockbuster drug Invega Sustenna | Lawsuits follow appeals court win for J&J in separate action with Teva and ...

In a 2022 decision involving Janssen and Pharmascience, the Federal Court found that the claims of Canadian Patent No. 2,655,335 (335 patent, relating to paliperidone palmitate (Janssen’s INVEGA ...

J&J sold more than $4.1 billion worth of Invega Sustenna and related drugs worldwide last year, with nearly $2.9 billion in U.S. sales, according to a company report.

As previously reported, the Federal Court released a pair of decisions relating to paliperidone palmitate (Janssen’s INVEGA SUSTENNA), finding in a summary trial that each of Pharmascience and ...

Meanwhile, Darzalex, a multiple myeloma drug JNJ markets with Genmab , brought $2.9B to the top line, while antipsychotic Invega Sustenna generated $1.1B with ~18% YoY and ~2% YoY growth ...

J&J sold more than $4.1 billion worth of Invega Sustenna and related drugs worldwide last year, with nearly $2.9 billion in U.S. sales, according to a company report.